Saturday, April 22, 2017 12:31:03 PM
1) http://ir.bioblastpharma.com/phoenix.zhtml?c=253658&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNTE2NjkyJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
Bioblast Pharma Ltd.
37 Dereh Menachem Begin St., 15th Floor
Tel-Aviv, Israel 6522042
April 6, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Request to Withdraw Registration Statement on Form F-1 (File No. 333-216238)
Ladies and Gentlemen:
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Bioblast Pharma Ltd. (the “Registrant”) hereby requests the immediate withdrawal of the above-referenced registration statement, together with all exhibits and amendments thereto (the “Registration Statement”). The Registration Statement was initially filed with the Securities and Exchange Commission (the “Commission”) on February 24, 2017.
The Registrant is requesting to withdraw the Registration Statement because it has elected not to pursue the sale of securities pursuant to the Registration Statement at this time. The Registration Statement was not declared effective by the Commission and the Registrant confirms that no securities were sold in connection with the offering contemplated by the Registration Statement. Pursuant to Rule 477(c) under the Securities Act, the Registrant respectfully advises the Commission that the Registrant may undertake a subsequent private offering in reliance on Rule 155(c) under the Securities Act.
The Registrant further requests that, in accordance with Rule 457(p) under the Securities Act and subject to compliance with the requirements thereof, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for potential future use.
Should you have any questions regarding this matter, please contact counsel to the Registrant, Shy Baranov, Esq., of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP at (617) 338-2932.
Very truly yours,
/s/ Fredric Price
Fredric Price
Executive Chairman of the Board of
Directors and Chief Executive Officer
2 Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid Requirements
http://finance.yahoo.com/news/bioblast-pharma-announces-plans-response-204830984.html;_ylt=AwrBT9VigPtY7ZYABJ5XNyoA;_ylu=X3oDMTByMjB0aG5zBGNvbG8DYmYxBHBvcwMxBHZ0aWQDBHNlYwNzYw--
Bioblast has a 180 day period, until October 9, 2017, to regain compliance with the $1.00 minimum bid price requirement. If at any time during this 180 day period, the closing bid price of the company’s ordinary shares is at least $1.00 for a minimum of ten consecutive business days, the company will regain compliance and the matter will be closed.
3) RSI in the oversold territory and looks to have bottomed out given #1 above.
Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.
Recent ENLV News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2024 12:30:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2024 08:30:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/23/2024 12:02:02 PM
- Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis • GlobeNewswire Inc. • 07/23/2024 12:00:00 PM
- Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/20/2024 12:04:56 PM
- Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/17/2024 12:03:18 PM
- Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/14/2024 08:30:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 12:05:31 PM
- Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/29/2024 08:20:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/29/2024 08:15:50 PM
- Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering • GlobeNewswire Inc. • 05/29/2024 08:15:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 12:13:35 PM
- Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering • GlobeNewswire Inc. • 05/28/2024 12:12:00 PM
- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Yet Another Biotech Stock Has Found Success During Tuesday's Session • AllPennyStocks.com • 04/16/2024 08:55:00 PM
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis • GlobeNewswire Inc. • 04/16/2024 11:50:00 AM
- Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis • GlobeNewswire Inc. • 04/11/2024 06:58:20 PM
- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis • GlobeNewswire Inc. • 04/11/2024 12:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 01:02:02 PM
- Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM